ATE413388T1 - Muskarin antagonisten - Google Patents
Muskarin antagonistenInfo
- Publication number
- ATE413388T1 ATE413388T1 AT03726436T AT03726436T ATE413388T1 AT E413388 T1 ATE413388 T1 AT E413388T1 AT 03726436 T AT03726436 T AT 03726436T AT 03726436 T AT03726436 T AT 03726436T AT E413388 T1 ATE413388 T1 AT E413388T1
- Authority
- AT
- Austria
- Prior art keywords
- sup
- formula
- compound
- muscarine antagonists
- methods
- Prior art date
Links
- UQOFGTXDASPNLL-XHNCKOQMSA-N Muscarine Chemical compound C[C@@H]1O[C@H](C[N+](C)(C)C)C[C@H]1O UQOFGTXDASPNLL-XHNCKOQMSA-N 0.000 title 1
- 239000005557 antagonist Substances 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 4
- 229940100578 Acetylcholinesterase inhibitor Drugs 0.000 abstract 1
- 239000000544 cholinesterase inhibitor Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
- C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
- C07D221/20—Spiro-condensed ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/92—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with a hetero atom directly attached to the ring nitrogen atom
- C07D211/96—Sulfur atom
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Other In-Based Heterocyclic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US37609302P | 2002-04-26 | 2002-04-26 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE413388T1 true ATE413388T1 (de) | 2008-11-15 |
Family
ID=29270760
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT03726436T ATE413388T1 (de) | 2002-04-26 | 2003-04-24 | Muskarin antagonisten |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US6890936B2 (https=) |
| EP (1) | EP1499596B1 (https=) |
| JP (2) | JP4527408B2 (https=) |
| CN (1) | CN1649845A (https=) |
| AT (1) | ATE413388T1 (https=) |
| AU (1) | AU2003228674A1 (https=) |
| CA (1) | CA2484217A1 (https=) |
| DE (1) | DE60324544D1 (https=) |
| ES (1) | ES2315494T3 (https=) |
| MX (1) | MXPA04010552A (https=) |
| WO (1) | WO2003091220A1 (https=) |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1622569B1 (en) | 2003-04-24 | 2015-12-02 | Incyte Corporation | Aza spiro alkane derivatives as inhibitors of metallproteases |
| CN101044134A (zh) | 2004-09-20 | 2007-09-26 | 塔加西普特公司 | 具有烟碱性胆碱能受体活性的氮杂螺烯和氮杂螺烷化合物 |
| EP2275095A3 (en) | 2005-08-26 | 2011-08-17 | Braincells, Inc. | Neurogenesis by muscarinic receptor modulation |
| AU2007299920A1 (en) * | 2006-09-19 | 2008-03-27 | Braincells, Inc. | PPAR Mediated Modulation of Neurogenesis |
| EP2076288A2 (en) * | 2006-09-22 | 2009-07-08 | Braincells, Inc. | Combination comprising an hmg-coa reductase inhibitor and a second neurogenic agent for treating a nervous system disorder and increasing neurogenesis |
| US20080108574A1 (en) * | 2006-09-27 | 2008-05-08 | Braincells, Inc. | Melanocortin receptor mediated modulation of neurogenesis |
| US8278345B2 (en) | 2006-11-09 | 2012-10-02 | Probiodrug Ag | Inhibitors of glutaminyl cyclase |
| ATE554085T1 (de) | 2006-11-30 | 2012-05-15 | Probiodrug Ag | Neue inhibitoren von glutaminylcyclase |
| JP5930573B2 (ja) | 2007-03-01 | 2016-06-15 | プロビオドルグ エージー | グルタミニルシクラーゼ阻害剤の新規使用 |
| EP2142514B1 (en) | 2007-04-18 | 2014-12-24 | Probiodrug AG | Thiourea derivatives as glutaminyl cyclase inhibitors |
| TW200902007A (en) * | 2007-05-25 | 2009-01-16 | Astrazeneca Ab | Spirocyclopropyl piperidine derivatives |
| US20100130477A1 (en) * | 2008-11-25 | 2010-05-27 | Astrazeneca Ab | Spirocyclobutyl Piperidine Derivatives |
| JP5934645B2 (ja) | 2009-09-11 | 2016-06-15 | プロビオドルグ エージー | グルタミニルシクラーゼ阻害剤としてのヘテロ環式誘導体 |
| AU2011215870B2 (en) | 2010-02-09 | 2016-01-28 | The Johns Hopkins University | Methods and compositions for improving cognitive function |
| JP6026284B2 (ja) | 2010-03-03 | 2016-11-16 | プロビオドルグ エージー | グルタミニルシクラーゼの阻害剤 |
| NZ602312A (en) | 2010-03-10 | 2014-02-28 | Probiodrug Ag | Heterocyclic inhibitors of glutaminyl cyclase (qc, ec 2.3.2.5) |
| WO2011131748A2 (en) | 2010-04-21 | 2011-10-27 | Probiodrug Ag | Novel inhibitors |
| US20110281853A1 (en) | 2010-05-12 | 2011-11-17 | Rishi Arora | Compositions and methods for treating or preventing atrial fibrillation |
| EP2686313B1 (en) | 2011-03-16 | 2016-02-03 | Probiodrug AG | Benzimidazole derivatives as inhibitors of glutaminyl cyclase |
| US20140206667A1 (en) | 2012-11-14 | 2014-07-24 | Michela Gallagher | Methods and compositions for treating schizophrenia |
| JP6433482B2 (ja) | 2013-03-15 | 2018-12-05 | エージンバイオ， インコーポレイテッド | 認知機能を改善するための方法および組成物 |
| WO2014144663A1 (en) | 2013-03-15 | 2014-09-18 | The Johns Hopkins University | Methods and compositions for improving cognitive function |
| RU2017118562A (ru) | 2014-10-31 | 2018-11-30 | Индивиор ЮКей Лимитед | Соединения-антагонисты дофаминового d3-рецептора |
| WO2016191288A1 (en) | 2015-05-22 | 2016-12-01 | Agenebio, Inc. | Extended release pharmaceutical compositions of levetiracetam |
| AU2018300980A1 (en) | 2017-07-12 | 2020-01-02 | Vanderbilt University | Antagonists of the muscarinic acetylcholine receptor M4 |
| ES2812698T3 (es) | 2017-09-29 | 2021-03-18 | Probiodrug Ag | Inhibidores de glutaminil ciclasa |
| IL273924B2 (en) | 2017-10-20 | 2024-07-01 | Univ Vanderbilt | Antagonists of the muscarinic acetylcholine receptor m4 |
| WO2019126559A1 (en) | 2017-12-20 | 2019-06-27 | Vanderbilt University | Antagonists of the muscarinic acetylcholine receptor m4 |
| TWI767148B (zh) * | 2018-10-10 | 2022-06-11 | 美商弗瑪治療公司 | 抑制脂肪酸合成酶(fasn) |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH04225953A (ja) * | 1990-05-07 | 1992-08-14 | Shionogi & Co Ltd | スピロ ジベンゾスベラン誘導体 |
| GB9309422D0 (en) * | 1993-05-07 | 1993-06-23 | Res Inst Medicine Chem | Chemical compounds |
| WO1999032489A1 (en) * | 1997-12-23 | 1999-07-01 | Alcon Laboratories, Inc. | Muscarinic agents and use thereof to treat glaucoma, myopia and various other conditions |
| JPWO2002085890A1 (ja) * | 2001-04-20 | 2004-08-12 | 萬有製薬株式会社 | ベンズイミダゾロン誘導体 |
-
2003
- 2003-04-24 CN CNA038094436A patent/CN1649845A/zh active Pending
- 2003-04-24 DE DE60324544T patent/DE60324544D1/de not_active Expired - Lifetime
- 2003-04-24 AU AU2003228674A patent/AU2003228674A1/en not_active Abandoned
- 2003-04-24 MX MXPA04010552A patent/MXPA04010552A/es unknown
- 2003-04-24 CA CA002484217A patent/CA2484217A1/en not_active Abandoned
- 2003-04-24 JP JP2003587783A patent/JP4527408B2/ja not_active Expired - Fee Related
- 2003-04-24 WO PCT/US2003/012694 patent/WO2003091220A1/en not_active Ceased
- 2003-04-24 EP EP03726436A patent/EP1499596B1/en not_active Expired - Lifetime
- 2003-04-24 AT AT03726436T patent/ATE413388T1/de not_active IP Right Cessation
- 2003-04-24 ES ES03726436T patent/ES2315494T3/es not_active Expired - Lifetime
- 2003-04-28 US US10/425,376 patent/US6890936B2/en not_active Expired - Fee Related
-
2009
- 2009-12-16 JP JP2009285736A patent/JP2010059213A/ja not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| MXPA04010552A (es) | 2005-01-25 |
| JP4527408B2 (ja) | 2010-08-18 |
| US6890936B2 (en) | 2005-05-10 |
| WO2003091220A1 (en) | 2003-11-06 |
| AU2003228674A1 (en) | 2003-11-10 |
| DE60324544D1 (de) | 2008-12-18 |
| US20040067972A1 (en) | 2004-04-08 |
| CN1649845A (zh) | 2005-08-03 |
| JP2006507220A (ja) | 2006-03-02 |
| ES2315494T3 (es) | 2009-04-01 |
| HK1068136A1 (en) | 2005-04-22 |
| CA2484217A1 (en) | 2003-11-06 |
| EP1499596A1 (en) | 2005-01-26 |
| EP1499596B1 (en) | 2008-11-05 |
| JP2010059213A (ja) | 2010-03-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE413388T1 (de) | Muskarin antagonisten | |
| IL166271A0 (en) | Pyrrolidinedione substituted piperidine phthalazone derivatives and pharmaceutical compositions containing the same | |
| UA88012C2 (uk) | Похідні хіназоліндіону як інгібітори parp | |
| SE0101675D0 (sv) | Novel composition | |
| ATE433447T1 (de) | Pyrimiidinverbindungen | |
| ATE425149T1 (de) | ANILINOPYRIMIDIN DERIVATE ALS ßJNK PATHWAY INHIBITORENß, ZUSAMMENSETZUNGEN UND DAMIT VERBUNDENE BEHANDLUNGSMETHODEN | |
| BRPI0410630A (pt) | antagonista de nk1 | |
| ATE478664T1 (de) | Azaphenanthridone-derivate und deren verwendung als parp-inhibitoren | |
| ATE453393T1 (de) | Verwendung von pyridylamiden als angiogenesehemmer | |
| IS6658A (is) | Ný efnasambönd | |
| DE602004008098D1 (de) | Substituierte 2h-ä1,2,4ütriazoloä4,3-aüpyrazine als gsk-3-inhibitoren | |
| DK0842934T3 (da) | 5-HT1F agonister | |
| ATE250590T1 (de) | Neuartiger p2x 7 rezeptor-antagonisten zur verwendung in der behandlung von entzündlichen, immuninduzierten erkrankungen oder erkrankungen des herz-kreislauf-systems | |
| BR0307833A (pt) | Sìntese controlada de ziprasidona e suas composições | |
| ATE374190T1 (de) | Tetrahydrochinazolinderivate als cfr-antagonisten | |
| ATE377602T1 (de) | Morphinanderivate und ihre medizinische anwendung | |
| DE60323942D1 (de) | Lipase-hemmende zusammensetzung | |
| ATE498600T1 (de) | Inden derivate als pharmazeutika | |
| ATE369348T1 (de) | Zyklisierte benzamid-neurokinin-antagonisten zur verwendung in therapie | |
| BR0212899A (pt) | Compostos orgânicos | |
| AP2001002188A0 (en) | 5HT1 antagonists for antidepressant therapy. | |
| ATE419242T1 (de) | Pyrrolidinylharnstoffderivate als angiogeneseinhibitoren | |
| ATE335739T1 (de) | Cak inhibitoren und deren verwendungen | |
| NO20002408D0 (no) | 5-HT1F antagonister | |
| DE60133914D1 (de) | Substituierte 4,5-dihydro-1,2,4-triazin-3-one, 1,2,4-triazin-3-one sowie deren verwendung als fungizide und insektizide |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |